Multi-targeted fibrosis tests

A method for treating an individual suffering from a liver fibrosis, comprising:

• determining in the individual the presence and severity of a liver fibrosis by:
• 1) performing at least 3 binary logistic regressions, or at least 3 other statistical analyses selected from linear discriminant analyses and multivariate analyses, on at least one variable, wherein the binary logistic regressions, or other statistical analyses, are performed on the same variable(s) but are each directed to a different single diagnostic target, thereby obtaining at least 3 scores;
• 2) combining the at least 3 scores obtained in step 1) in a multiple linear regression to obtain a new multi-targeted score, thereby determining the presence and severity of a liver fibrosis in the individual;
• and
• implementing an adapted patient care depending on the severity of the liver fibrosis, comprising:
• monitoring the individual by assessing the liver fibrosis severity at regular intervals,
• administering without delay at least one therapeutic agent to the individual, wherein said at least one therapeutic agent is an antifibrotic agent selected from the group consisting of simtuzumab, GR-MD-02, stem cell transplantation, Phyllanthus urinaria, Fuzheng Huayu, S-adenosyl-L-methionine, S-nitrosol-N-acetylcystein, silymarin, phosphatidylcholine, N-acetylcysteine, resveratrol, vitamin E, losartan, telmisartan, naltrexone, RF260330, sorafenib, imatinib mesylate, nilotinib, INT747, FG-3019, oltipraz, pirfenidone, halofuginone, polaorezin, gliotoxin, sulfasalazine, rimonabant, and combinations thereof, or
• wherein said at least one therapeutic agent is for treating the underlying cause responsible for the liver fibrosis, and/or
• starting a complication screening program for applying early prophylactic or curative treatment.